Head to Head Comparison: Adamis Pharmaceuticals Corporation (ADMP) versus Its Rivals

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Adamis Pharmaceuticals Corporation to similar businesses based on the strength of its dividends, institutional ownership, valuation, analyst recommendations, profitability, risk and earnings.

Institutional & Insider Ownership

10.1% of Adamis Pharmaceuticals Corporation shares are held by institutional investors. Comparatively, 42.0% of shares of all “Pharmaceuticals” companies are held by institutional investors. 9.6% of Adamis Pharmaceuticals Corporation shares are held by company insiders. Comparatively, 12.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Adamis Pharmaceuticals Corporation and its peers gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Adamis Pharmaceuticals Corporation $6.47 million -$19.43 million N/A
Adamis Pharmaceuticals Corporation Competitors $8.27 billion $1.10 billion 146.54

Adamis Pharmaceuticals Corporation’s peers have higher revenue and earnings than Adamis Pharmaceuticals Corporation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Adamis Pharmaceuticals Corporation and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adamis Pharmaceuticals Corporation 0 0 3 0 3.00
Adamis Pharmaceuticals Corporation Competitors 862 3816 6859 186 2.54

Adamis Pharmaceuticals Corporation currently has a consensus price target of $9.83, suggesting a potential upside of 107.02%. As a group, “Pharmaceuticals” companies have a potential upside of 26.44%. Given Adamis Pharmaceuticals Corporation’s stronger consensus rating and higher probable upside, equities analysts plainly believe Adamis Pharmaceuticals Corporation is more favorable than its peers.

Risk and Volatility

Adamis Pharmaceuticals Corporation has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals Corporation’s peers have a beta of 31.77, suggesting that their average stock price is 3,077% more volatile than the S&P 500.

Profitability

This table compares Adamis Pharmaceuticals Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adamis Pharmaceuticals Corporation -158.51% -69.03% -47.51%
Adamis Pharmaceuticals Corporation Competitors -2,390.82% -60.32% -8.61%

Summary

Adamis Pharmaceuticals Corporation peers beat Adamis Pharmaceuticals Corporation on 8 of the 12 factors compared.

Adamis Pharmaceuticals Corporation Company Profile

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply